These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1890 related items for PubMed ID: 26214622

  • 1. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?
    Ulas A, Avci N, Kos T, Cubukcu E, Olmez OF, Bulut N, Degirmenci M.
    J BUON; 2015; 20(3):714-22. PubMed ID: 26214622
    [Abstract] [Full Text] [Related]

  • 2. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2-) Breast Cancer.
    Hu Y, Wang S, Ding N, Li N, Huang J, Xiao Z.
    Clin Breast Cancer; 2020 Aug; 20(4):e403-e409. PubMed ID: 32201163
    [Abstract] [Full Text] [Related]

  • 3. Preoperative neutrophil-to-lymphocyte ratio and plateletto- lymphocyte ratio as new prognostic factors for patients with colorectal cancer.
    Mahsuni Sevinc M, Riza Gunduz U, Kinaci E, Armagan Aydin A, Bayrak S, Umar Gursu R, Gunduz S.
    J BUON; 2016 Aug; 21(5):1153-1157. PubMed ID: 27837617
    [Abstract] [Full Text] [Related]

  • 4. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.
    Graziano V, Grassadonia A, Iezzi L, Vici P, Pizzuti L, Barba M, Quinzii A, Camplese A, Di Marino P, Peri M, Veschi S, Alberti S, Gamucci T, Di Gioacchino M, De Tursi M, Natoli C, Tinari N.
    Breast; 2019 Apr; 44():33-38. PubMed ID: 30611095
    [Abstract] [Full Text] [Related]

  • 5. The preoperative neutrophil-lymphocyte ratio predicts recurrence and survival among patients undergoing R0 resections of adenocarcinomas of the esophagogastric junction.
    Yuan D, Zhu K, Li K, Yan R, Jia Y, Dang C.
    J Surg Oncol; 2014 Sep; 110(3):333-40. PubMed ID: 24889121
    [Abstract] [Full Text] [Related]

  • 6. The prognostic significance of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in giant cell tumor of the extremities.
    Chen Z, Zhao G, Chen F, Xia J, Jiang L.
    BMC Cancer; 2019 Apr 08; 19(1):329. PubMed ID: 30961549
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
    Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporté I, Kramar A, PHARE trial investigators.
    Lancet Oncol; 2013 Jul 08; 14(8):741-8. PubMed ID: 23764181
    [Abstract] [Full Text] [Related]

  • 9. Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer.
    Zhao G, Liu N, Wang S, Guo J, Song X, Qi Y, Qiu W, Lv J.
    Medicine (Baltimore); 2020 Mar 08; 99(10):e19405. PubMed ID: 32150090
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Preoperative platelet-lymphocyte ratio is superior to neutrophil-lymphocyte ratio as a prognostic factor for soft-tissue sarcoma.
    Que Y, Qiu H, Li Y, Chen Y, Xiao W, Zhou Z, Zhang X.
    BMC Cancer; 2015 Oct 02; 15():648. PubMed ID: 26432433
    [Abstract] [Full Text] [Related]

  • 16. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of outcomes in inflammatory breast cancer.
    Al Jarroudi O, El Bairi K, Abda N, Zaimi A, Jaouani L, Chibani H, Afqir S.
    Biomark Med; 2021 Oct 02; 15(14):1289-1298. PubMed ID: 34486882
    [Abstract] [Full Text] [Related]

  • 17. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.
    Chen Y, Chen K, Xiao X, Nie Y, Qu S, Gong C, Su F, Song E.
    BMC Cancer; 2016 May 19; 16():320. PubMed ID: 27198767
    [Abstract] [Full Text] [Related]

  • 18. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, Templeton AJ, Früh M.
    Lung Cancer; 2017 Sep 19; 111():176-181. PubMed ID: 28838390
    [Abstract] [Full Text] [Related]

  • 19. Pre-treatment neutrophil to lymphocyte ratio is a predictor of prognosis in endometrial cancer.
    Haruma T, Nakamura K, Nishida T, Ogawa C, Kusumoto T, Seki N, Hiramatsu Y.
    Anticancer Res; 2015 Jan 19; 35(1):337-43. PubMed ID: 25550569
    [Abstract] [Full Text] [Related]

  • 20. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
    Arslan UY, Turker I, Aksoy S, Oksuzoglu B, Helvaci K, Yildirim Ozdemir N, Uyeturk U, Uysal Sonmez O, Budakoglu B, Zengin N.
    J BUON; 2013 Jan 19; 18(3):585-93. PubMed ID: 24065468
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 95.